Enveric Biosciences, Inc. Cash Flow Statement
ENVB|3 years of annual SEC 10-K data (FY2017-FY2019)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
Enveric Biosciences, Inc. used $3M in operating cash flow in FY2019.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2019 | FY2018 | FY2017 |
|---|---|---|---|
| Net Income | -$16.9M | -$9.1M | -$2.8M |
| Depreciation & Amortization | $2.9M | $3.2M | $1.4M |
| Operating Cash Flow | -$2.6M | -$2.7M | -$2.7M |